<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>345-METHYLDOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHYLDOPA" rxcui="6876">
<ATC code="C02AB" />
<ATC code="C02AB01" />
<ATC code="C02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="1431589">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the methyldopa (formation of complexes)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the methyldopa (more than two hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>345-METHYLDOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHYLDOPA" rxcui="6876">
<ATC code="C02AB" />
<ATC code="C02AB01" />
<ATC code="C02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible decrease of the doses of levodopa.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>345-METHYLDOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHYLDOPA" rxcui="6876">
<ATC code="C02AB" />
<ATC code="C02AB01" />
<ATC code="C02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="N05AN01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of lithium which can attain toxic values, with signs of overdose of lithium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of lithium. </COMMENT>
</INTERACTION>
</INTERACTIONS>
